Prognostic significance of histologic differentiation, carcinoembryonic antigen value, and lymphovascular invasion in stage I non-small cell lung cancer

被引:32
作者
Kuo, Shuenn-Wen
Chen, Jin-Shing
Huang, Pei-Ming
Hsu, Hsao-Hsun
Lai, Hong-Shiee
Lee, Jang-Ming [1 ,2 ]
机构
[1] Natl Taiwan Univ Hosp, Dept Surg, Div Thorac Surg, Taipei 10002, Taiwan
[2] Natl Taiwan Univ, Coll Med, Taipei 10002, Taiwan
关键词
VINORELBINE PLUS CISPLATIN; RISK-FACTORS; 7TH EDITION; RECURRENCE; SURVIVAL;
D O I
10.1016/j.jtcvs.2014.04.038
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: For stage I non-small cell lung cancer (NSCLC), the only 2 prognostic factors incorporated into the seventh edition of the TNM staging system were tumor size and visceral pleural invasion. However, with this staging system, the prognostic precision of survival has proved elusive, suggesting the need to include additional prognostic factors. To improve prognostic applications and treatment decisions, we investigated clinicopathologic factors affecting progression-free survival in patients with surgically resected stage I NSCLC. Methods: From January 2004 to December 2011, we retrospectively reviewed the clinicopathologic characteristics of 758 consecutive patients with surgically resected stage I NSCLC at the National Taiwan University Hospital. Results: The 5-year progression-free survival rate was 82.3% and 64.0% for those with stage IA (n = 481) and stage IB (n = 277), respectively. Multivariate analysis revealed poor or moderate histologic differentiation and elevated preoperative serum carcinoembryonic antigen were statistically significant risk factors for recurrence in patients with stage IA. Poor or moderate histologic differentiation, elevated preoperative serum carcinoembryonic antigen, lymphovascular invasion, and tumor size > 2 cm were statistically significant risk factors for recurrence in patients with stage I NSCLC. The 5-year progression-free survival rate was 93.0%, 73.8%, and 40.6% for stage I patients with no, 1 or 2, and > 2 risk factors, respectively (P <. 001). Conclusions: In addition to tumor size, we identified 3 other independent risk factors for recurrence in patients with stage I NSCLC. These 3 risk factors warrant consideration as additional predictors in the next version of the TNM staging system.
引用
收藏
页码:1200 / +
页数:11
相关论文
共 21 条
  • [11] Pathogenesis of lung cancer - 100 year report
    Miller, YE
    [J]. AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 2005, 33 (03) : 216 - 223
  • [12] Prognostic impact of intratumoral vessel invasion in completely resected pathologic stage I non-small cell lung cancer
    Miyoshi, Kentaroh
    Moriyama, Shigeharu
    Kunitomo, Tadayoshi
    Nawa, Sugato
    [J]. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2009, 137 (02) : 429 - 434
  • [13] Effect of histologic type and smoking status on interpretation of serum carcinoembryonic antigen value in non-small cell lung carcinoma
    Okada, M
    Nishio, W
    Sakamoto, T
    Uchino, K
    Yuki, T
    Nakagawa, A
    Tsubota, N
    [J]. ANNALS OF THORACIC SURGERY, 2004, 78 (03) : 1004 - 1010
  • [14] Prognostic significance of perioperative serum carcinoembryonic antigen in non-small cell lung cancer: Analysis of 1,000 consecutive resections for clinical stage I disease
    Okada, M
    Nishio, W
    Sakamoto, T
    Uchino, K
    Yuki, T
    Nakagawa, A
    Tsubota, N
    [J]. ANNALS OF THORACIC SURGERY, 2004, 78 (01) : 216 - 221
  • [15] Estimates of the world-wide prevalence of cancer for 25 sites in the adult population
    Pisani, P
    Bray, F
    Parkin, DM
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2002, 97 (01) : 72 - 81
  • [16] 7th Edition of the AJCC Cancer Staging Manual: Esophagus and Esophagogastric Junction
    Rice, Thomas W.
    Blackstone, Eugene H.
    Rusch, Valerie W.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2010, 17 (07) : 1721 - 1724
  • [17] Serum carcinoembryonic antigen level in surgically resected clinical stage I patients with non-small cell lung cancer
    Sawabata, N
    Ohta, M
    Takeda, S
    Hirano, H
    Okumura, Y
    Asada, H
    Maeda, H
    [J]. ANNALS OF THORACIC SURGERY, 2002, 74 (01) : 174 - 179
  • [18] Special treatment issues in lung. cancer - ACCP evidence-based clinical practice guidelines (2nd edition)
    Shen, K. Robert
    Meyers, Bryan F.
    Larner, Janes M.
    Jones, David R.
    [J]. CHEST, 2007, 132 (03) : 290S - 305S
  • [19] Mass screening for lung cancer with mobile spiral computed tomography scanner
    Sone, S
    Takashima, S
    Li, F
    Yang, ZG
    Honda, T
    Maruyama, Y
    Hasegawa, M
    Yamanda, T
    Kubo, K
    Hanamura, K
    Asakura, K
    [J]. LANCET, 1998, 351 (9111) : 1242 - 1245
  • [20] Travis WD, 2004, PATHOLOGY GENETICS T, P10